Molecular Characterisation and Identification of Biomarkers for Early Diagnosis of Family Exocrine Pancreatic Cancer (Q3155528): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): Exocrine pancreatic cancer (PEC) will be the second largest cause of cancer death in 2020. Early diagnosis is essential to achieve higher survival rates (5 % at 5 years). In our Family Pancreatic Cancer Registry (FCP) with more than 30 families, we will study and follow families at risk of PSC to identify biomarkers in the blood for early diagnosis and molecularly characterise patients with CPF and their healthy family members with or without...) |
(Created claim: summary (P836): Exocrine pancreatic cancer (PEC) will be the second largest cause of cancer death in 2020. Early diagnosis is essential to achieve higher survival rates (5 % at 5 years). In our Family Pancreatic Cancer Registry (FCP) with more than 30 families, we will study and follow families at risk of PSC to identify biomarkers in the blood for early diagnosis and molecularly characterise patients with CPF and their healthy family members with or without PS...) |
||||||||||||||
| Property / summary | |||||||||||||||
Exocrine pancreatic cancer (PEC) will be the second largest cause of cancer death in 2020. Early diagnosis is essential to achieve higher survival rates (5 % at 5 years). In our Family Pancreatic Cancer Registry (FCP) with more than 30 families, we will study and follow families at risk of PSC to identify biomarkers in the blood for early diagnosis and molecularly characterise patients with CPF and their healthy family members with or without PSC. Our objectives are to: a) Continue and expand to other centers the Registry and Biobank of Families with CPF b) Linearly follow healthy family members with periodic taking of their biological samples and imaging tests, and identify the clinical and genetic differences between those who develop cancer and those who do not develop it c) Molecular characterisation with massive ultrasequence of PSC and germline patients and their healthy relatives d) Validate for screening the miRNAs identified in the previous project e) Characterise, for blood screening, mutations in RAS, CDKN2A, SMAD4 and TP53 with digital PCR Beaming technology from Sysmex Inostics with greater sensitivity f) Validate the diagnostic predictive power of genetic signature in CPF that we are studying in the context of the ERANET-TRANSCAN project in patients with resected pancreatic cancer g) Increase the profitability of CTC screening without eliminating accompanying hematopoietic cells (English) | |||||||||||||||
| Property / summary: Exocrine pancreatic cancer (PEC) will be the second largest cause of cancer death in 2020. Early diagnosis is essential to achieve higher survival rates (5 % at 5 years). In our Family Pancreatic Cancer Registry (FCP) with more than 30 families, we will study and follow families at risk of PSC to identify biomarkers in the blood for early diagnosis and molecularly characterise patients with CPF and their healthy family members with or without PSC. Our objectives are to: a) Continue and expand to other centers the Registry and Biobank of Families with CPF b) Linearly follow healthy family members with periodic taking of their biological samples and imaging tests, and identify the clinical and genetic differences between those who develop cancer and those who do not develop it c) Molecular characterisation with massive ultrasequence of PSC and germline patients and their healthy relatives d) Validate for screening the miRNAs identified in the previous project e) Characterise, for blood screening, mutations in RAS, CDKN2A, SMAD4 and TP53 with digital PCR Beaming technology from Sysmex Inostics with greater sensitivity f) Validate the diagnostic predictive power of genetic signature in CPF that we are studying in the context of the ERANET-TRANSCAN project in patients with resected pancreatic cancer g) Increase the profitability of CTC screening without eliminating accompanying hematopoietic cells (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Exocrine pancreatic cancer (PEC) will be the second largest cause of cancer death in 2020. Early diagnosis is essential to achieve higher survival rates (5 % at 5 years). In our Family Pancreatic Cancer Registry (FCP) with more than 30 families, we will study and follow families at risk of PSC to identify biomarkers in the blood for early diagnosis and molecularly characterise patients with CPF and their healthy family members with or without PSC. Our objectives are to: a) Continue and expand to other centers the Registry and Biobank of Families with CPF b) Linearly follow healthy family members with periodic taking of their biological samples and imaging tests, and identify the clinical and genetic differences between those who develop cancer and those who do not develop it c) Molecular characterisation with massive ultrasequence of PSC and germline patients and their healthy relatives d) Validate for screening the miRNAs identified in the previous project e) Characterise, for blood screening, mutations in RAS, CDKN2A, SMAD4 and TP53 with digital PCR Beaming technology from Sysmex Inostics with greater sensitivity f) Validate the diagnostic predictive power of genetic signature in CPF that we are studying in the context of the ERANET-TRANSCAN project in patients with resected pancreatic cancer g) Increase the profitability of CTC screening without eliminating accompanying hematopoietic cells (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 15:50, 12 October 2021
Project Q3155528 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Molecular Characterisation and Identification of Biomarkers for Early Diagnosis of Family Exocrine Pancreatic Cancer |
Project Q3155528 in Spain |
Statements
86,625.0 Euro
0 references
173,250.0 Euro
0 references
50.0 percent
0 references
1 January 2016
0 references
31 March 2020
0 references
FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
El cáncer de páncreas exocrino (CPE) será la segunda causa de muerte por cáncer en 2020. Su diagnóstico precoz es fundamental para conseguir mayores tasas de supervivencia (5% a los 5 años). En nuestro Registro de Cáncer de Páncreas Familiar (CPF) con más de 30 familias, vamos a estudiar y seguir a los familiares a riesgo de CPE para identificar biomarcadores en sangre para su diagnóstico precoz y caracterizar molecularmente a los pacientes con CPF y a sus familiares sanos con o sin CPE. Nuestros objetivos son: a) Continuar y expandir a otros centros el Registro y Biobanco de familias con CPF b) Seguir linealmente a los familiares sanos con toma periódica de sus muestras biológicas y pruebas de imagen, e identificar las diferencias clínicas y genéticas entre los que desarrollan cáncer y los que no lo desarrollan c) Caracterización molecular con ultrasecuenciación masiva de los CPE y de la línea germinal de los pacientes con CPF y de sus familiares sanos d) Validar para el cribado los miRNAs identificados en el proyecto previo e) Caracterizar, para el cribado en sangre, las mutaciones en RAS, CDKN2A, SMAD4 y TP53 con tecnología PCR digital Beaming de Sysmex Inostics con mayor sensibilidad f) Validar el poder de predicción diagnóstica de la firma genética en CPF que estamos estudiando en el contexto del proyecto ERANET-TRANSCAN en los pacientes con cáncer de páncreas esporádico resecado g) Incrementar la rentabilidad del cribado con CTC, sin eliminar las células hematopoyéticas acompañantes (Spanish)
0 references
Exocrine pancreatic cancer (PEC) will be the second largest cause of cancer death in 2020. Early diagnosis is essential to achieve higher survival rates (5 % at 5 years). In our Family Pancreatic Cancer Registry (FCP) with more than 30 families, we will study and follow families at risk of PSC to identify biomarkers in the blood for early diagnosis and molecularly characterise patients with CPF and their healthy family members with or without PSC. Our objectives are to: a) Continue and expand to other centers the Registry and Biobank of Families with CPF b) Linearly follow healthy family members with periodic taking of their biological samples and imaging tests, and identify the clinical and genetic differences between those who develop cancer and those who do not develop it c) Molecular characterisation with massive ultrasequence of PSC and germline patients and their healthy relatives d) Validate for screening the miRNAs identified in the previous project e) Characterise, for blood screening, mutations in RAS, CDKN2A, SMAD4 and TP53 with digital PCR Beaming technology from Sysmex Inostics with greater sensitivity f) Validate the diagnostic predictive power of genetic signature in CPF that we are studying in the context of the ERANET-TRANSCAN project in patients with resected pancreatic cancer g) Increase the profitability of CTC screening without eliminating accompanying hematopoietic cells (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI15_02101
0 references